Cerbios-Pharma and PROVEO return to World ADC conference with enhanced one-stop offer
Press Release | Cerbios-Pharma SA
NOVEMBER 08, 2018
Lugano, Switzerland: – Cerbios-Pharma SA (Cerbios) will be a key presence at November’s 9th World ADC conference in San Diego as part of the multinational PROVEO Alliance to promote advanced integrated solutions in antibody drug conjugates.
Proveo and Cerbios are returning to San Diego after highly successful participations at the past three World ADC conferences in Europe and the USA.
The Cerbios team, including CEO, Dr. Gabriel Haering, COO Dr. Denis Angioletti, R&D Senior Manager Dr. Vitor Sousa and Business Development Dr. Matteo Piazza will be present on site, presenting PROVEO and Cerbios offer as a one stop shop for ADC development and cGMP manufacturing.
“We will be reaching out to pharmaceutical companies involved in ADC, oncology and bioventures, along with start-ups in the healthcare sector focused on oncology,” said Dr. Denis Angioletti.
Extended conjugation services
Cerbios-Pharma has recently extended its core conjugation process development expertise in HPAIs and Bio conjugation, its CMO offer includes enhanced ADC manufacturing capabilities in collaboration with PROVEO partners AGC Biologics and Oncotec.
“We will be happy for this great opportunity to present our CDMO services for optimizing ADC payloads and conjugation, as part of the overall PROVEO offer as a one stop shop for ADC,” said Dr. Angioletti.
“We will also be able to provide detail on our specific GMP capabilities in handling toxic payloads, as well as our focus on conjugation process development and manufacturing”, added Denis Angioletti.
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of both chemical and biological APIs for its partners world-wide.
Cerbios’ is a global leading supplier of a portfolio of Generic APIs primarily used for the treatment of Respiratory and Dermatological disorders as well as in Oncology.
Exclusive, CDMO services are offered for the development and manufacturing of HPAIs, , monoclonal antibodies, recombinant proteins, Antibody Drug Conjugates (ADCs) and pharma probiotics.
Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios’ commercial products are marketed worldwide but primarily in Europe, USA, Japan and India.
Since 2015, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with AGC Biologics of Denmark and with Germany’s Oncotec.
PROVEO can offer a ADCs end-to-end service from substance development up-to manufacturing and fill & finish.
About World ADC 2018
The World ADC Conference is the industry’s longest standing and most comprehensive event devoted to Antibody Drug Conjugate technology and solutions.
The event aims to generate new insights and connections to promote development of more clinically impactful ADCs.
The 9th conference, ADC World 2018, will be a four-day event opening November 12 at the Marriott Marquis & Marina, in San Diego, California.
The 2018 conference is likely to attract more than 650 professional delegates representing some 220 organizations to hear more than 90 industry expert speakers discuss a wide range of topics including payloads with differentiated mechanisms of action, ADC clinical pharmacology and leading-edge processes for more efficient ADC manufacturing
The event is organized by Hanson Wade with more information at: http://worldadc-usa.com/.
Dr. Matteo Piazza, Business Development Manager, Cerbios-Pharma SA
Tel: +41 79 2532664